Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 22, 2011. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Purchase Date: November 22, 2011.
- Price Range: Highest price paid was 1,367 pence per share; lowest price paid was 1,345 pence per share.
- Treasury Holdings (Settled): 521,462,927 shares (9.36% of total issued share capital).
- Treasury Holdings (Including Unsettled): 525,162,927 shares (10.40% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,051,581,782 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,500,000 shares, increasing the company's treasury stock holdings. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 1,500,000 share repurchase based on the weighted average price between 1,345 and 1,367 pence.
- Confirm the impact of the 10.40% treasury holding on total voting rights calculations.
- Check subsequent filings for the settlement status of the 3,700,000 shares noted as "purchased but not yet settled."
- Review the remaining authorization for share buybacks under the May 5, 2011 shareholder mandate.